VisEn Medical, Inc.

VisEn Acquires Key Fluorescence Agent Intellectual Property Portfolio and Technology Platforms from Bayer Schering Pharma

VisEn Acquires Key Fluorescence Agent Intellectual Property Portfolio and Technology Platforms from Bayer Schering Pharma

January 28, 2010

Consolidates the Leading Intellectual Property Positions and Technologies In Fluorescence In Vivo Imaging Agents

BG Medicine, Inc.

BG Medicine Files Registration Statement for Proposed Initial Public Offering

BG Medicine Files Registration Statement for Proposed Initial Public Offering

January 29, 2010

Waltham, MA - January 29, 2010 - BG Medicine, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range of the offering have not yet been determined.

Pervasis Therapeutics, Inc.

Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel®

Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel®

February 1, 2010

Agreement Follows Recent Publication of Data for Lead Programs in ESRD, PAD

CAMBRIDGE, Mass., Feb. 1 /PRNewswire/ -- Pervasis Therapeutics, Inc. today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of a pivotal Phase 3 clinical trial for Vascugel®, an investigational new drug for the prevention of hemodialysis access graft failure. The agreement was made under the FDA's Special Protocol Assessment (SPA) procedure. Pervasis expects to initiate the study in 2010.

LS9

LS9 Purchases Florida Site to Manufacture Renewable Petroleum

LS9 Purchases Florida Site to Manufacture Renewable Petroleum

February 3, 2010

Florida Facility Will Demonstrate Commercial Capabilities and Create Local Jobs

South San Francisco, CA – February 3, 2010 – LS9, the Renewable Petroleum Company™, today announced the acquisition of an existing production facility in Okeechobee, Florida. The facility will be retrofitted to accommodate LS9’s proprietary one-step fermentation process that converts renewable raw materials into low-cost, low carbon transportation fuels and chemicals.

Eleven Biotherapeutics, Inc.

Eleven Biotherapeutics Completes $35 Million Series A Funding to Advance Pipeline of Innovative Protein-Based Therapeutics

Eleven Biotherapeutics Completes $35 Million Series A Funding to Advance Pipeline of Innovative Protein-Based Therapeutics

February 17, 2010

Backed by Flagship Ventures and Third Rock Ventures

AVEO Pharmaceuticals, Inc.

AVEO Pharma Sets IPO Terms

AVEO Pharma Sets IPO Terms

February 23, 2010

AVEO Pharmaceuticals Inc., a Cambridge, Mass.-based oncology drug company, has set its IPO terms to seven million common shares being offered at between $13 and $15 per share. It would have an initial market cap of approximately $415 million, were it to price at the high end of its range.

The company plans to trade on the Nasdaq under ticker symbol AVEO, with J.P. Morgan and Morgan Stanley serving as co-lead underwriters.

Joule Unlimited, Inc.

Joule Named Among 50 Most Innovative Companies in the World

Joule Named Among 50 Most Innovative Companies in the World

March 2, 2010

MIT’s Technology Review cites Joule’s world-changing potential as part of the 2010 TR50

TransMedics, Inc.

TransMedics, Inc. Secures $36 Million Round of Financing Lead by Foundation Capital and Kleiner Perkins Caufield & Byers

TransMedics, Inc. Secures $36 Million Round of Financing Lead by Foundation Capital and Kleiner Perkins Caufield & Byers

March 4, 2010

ANDOVER, Mass., March 4 /PRNewswire/ -- TransMedics, Inc., a leading medical device company focusing on delivering the next standard of care for solid organ transplantation worldwide, announced today the closing of a $36 million financing round. The financing was lead by Foundation Capital and Kleiner Perkins Caufield & Byers (KPCB) and also included investments by Flagship Ventures and by several existing investors.

Acceleron Pharma, Inc.

Acceleron Recognized by The Wall Street Journal as One of the Top 50 Venture-Backed Companies in the United States

Acceleron Recognized by The Wall Street Journal as One of the Top 50 Venture-Backed Companies in the United States

March 10, 2010

CAMBRIDGE, Mass. – March 10, 2010 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat and the vasculature, today announced that it was recognized by VentureSource, a unit of Wall Street Journal owner News Corp. as one of the top 50 venture capital-backed companies in the United States.

VisEn Medical, Inc.

VisEn Launches New VivoTag® 680 XL Fluorescence Molecular Imaging Label

VisEn Launches New VivoTag® 680 XL Fluorescence Molecular Imaging Label

March 11, 2010

Extends VisEn’s Leading Fluorescence Molecular Imaging Labeling Portfolio to Enable Enhanced Imaging Applications of Biomarkers in Research and Drug Development

BEDFORD, MA (March 11, 2010)—VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new VivoTag® 680 XL fluorescent dye for labeling biomolecules in a broad range of in vitro and in vivo imaging applications.